Atlas Trials

A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease

Clinical trial NCT01933022 · TERMINATED

Trial details

NCT number
NCT01933022
Sponsor
Astellas Pharma Europe Ltd.
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Metastatic Prostate Cancer
Start date
2014-08-01
Primary completion
2015-08-01
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.